סקירה זו אשר זכתה לפרסום בינלאומי מובאת כאן כתקציר, באנגלית, בהמלצתו של פרופ' קרמר :
Presentation, Diagnosis, and Outcome in 142 Cases in Israel and Review of 640 Cases From the Literature
Gershon Fink, MD; Tali Krelbaum, MD; Alon Yellin, MD; Daniel Bendayan, MD; Milton Saute, MD; Mendel Glazer, MD and Mordechai R. Kramer, MD, FCCP
* From the Pulmonology Institute (Drs. Fink, Krelbaum, Bendayan, and Kramer), Rabin Medical Center, Beilinson Campus, Petah Tiqva; the Department of Thoracic Surgery (Dr. Yellin), Sheba Medical Center, Tel Hashomer; Carmel Medical Center (Dr. Saute), Haifa; and the Pulmonary Institute, Hadassah University Hospital (Dr. Glazer), Jerusalem, Israel.
Correspondence to: Mordechai R. Kramer, MD, FCCP, Pulmonology Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqva 49100, Israel; e-mail: email@example.com
Objective: To determine the characteristic features and outcome of pulmonary carcinoid tumors in Israel.
Methods: Retrospective analysis of the clinicopathologic data and outcome of patients from four major hospitals in Israel in the last 20 years.
Results: There were 142 cases of pulmonary carcinoid tumors: typical (n = 128) and atypical (n = 14). We calculated an annual incidence of about 2.3 to 2.8 cases per 1 million population. The ratio of female to male patients was 1.6:1. The prevalence of smoking was similar to the general population in patients with typical carcinoids and twice as high in the atypical group. Bronchial obstruction was the cause of most of the presenting symptoms and signs and included obstructive pneumonitis, pleuritic pain, atelectasis, and dyspnea (41%). Carcinoid syndrome was extremely rare and occurred in only one patient with metastatic disease. Most of the tumors (68%) arose in the major bronchi. Diagnosis was made using fiberoptic bronchoscopy in 52% of patients without evidence of endobronchial hemorrhage. Nodal involvement and distant metastases occurred in 57% and 21%, respectively, in the atypical group, and 10% and 3%, respectively, in the typical group. The treatment of choice was surgical: lobectomy (56%) or pneumonectomy (16%). The respective 5-year survival rates for patients with typical and atypical tumors were 89% and 75% (not significant), and the 10-year survival rates were 82% and 56% (p < 0.05). A review of large series from the literature is presented.
Conclusion: Pulmonary carcinoid is an uncommon tumor in the Israeli population. With early diagnosis and aggressive surgical therapy, long-term prognosis is excellent.
Key Words: pulmonary carcinoid • pulmonary obstruction
Copyright © 2001 by the American College of Chest Physicians.